このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

PharmaCyte Biotech マネジメント

マネジメント基準チェック /24

PharmaCyte Biotech'sの CEO はJosh Silvermanで、 Oct2022年に任命され、の在任期間は 1.67年です。の年間総報酬は$ 197.92Kで、 94.7%給与と5.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.59%を直接所有しており、その価値は$ 110.50K 。経営陣と取締役会の平均在任期間はそれぞれ5.5年と2.4年です。

主要情報

Josh Silverman

最高経営責任者

US$197.9k

報酬総額

CEO給与比率	94.7%
CEO在任期間	1.7yrs
CEOの所有権	0.6%
経営陣の平均在職期間	5.5yrs
取締役会の平均在任期間	2.4yrs

経営陣の近況

Recent updates

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Mar 22

PharmaCyte Biotech says CEO to step down, announces strategic review of business

Oct 07

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Aug 15

Is This A Good Time To Invest In PharmaCyte?

Jan 07

PharmaCyte Biotech: Buy The 'Dump'

Aug 21

CEO報酬分析

PharmaCyte Biotech の収益と比較して、Josh Silverman の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jan 31 2024	n/a	n/a	-US$15m
Oct 31 2023	n/a	n/a	-US$10m
Jul 31 2023	n/a	n/a	-US$10m
Apr 30 2023	US$198k	US$188k	-US$4m

報酬と市場: Joshの総報酬 ($USD 197.92K ) は、 US市場 ($USD 673.68K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Joshの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Josh Silverman (54 yo)

1.7yrs

在職期間

US$197,917

報酬

Mr. Joshua N. Silverman, also known as Josh, serves as an Independent Director at Femasys Inc. since November 21, 2023. He serves as Interim Chief Executive Officer of PharmaCyte Biotech, Inc. since Octobe...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Joshua Silverman	Interim CEO	1.7yrs	US$197.92k	0.59% $ 104.5k
Carlos Trujillo	Chief Financial Officer	7.3yrs	US$385.26k	0.12% $ 21.7k
Jose Iglesias	Consulting Chief Medical Officer	3.8yrs	データなし	データなし
Hans-Peter Hammes	Member of Medical & Scientific Advisory Board and Consultant	8.6yrs	データなし	データなし

5.5yrs

平均在職期間

66yo

平均年齢

経験豊富な経営陣: PMCBの経営陣は経験豊富で経験豊富です（平均在職期間は5.5年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Joshua Silverman	Interim CEO	1.8yrs	US$197.92k	0.59% $ 104.5k
Hans-Peter Hammes	Member of Medical & Scientific Advisory Board and Consultant	8.6yrs	データなし	データなし
Robert Weinstein	Independent Director	1.6yrs	US$18.75k	0% $ 0
Brian Salmons	Member of Medical & Scientific Advisory Board	8.1yrs	データなし	データなし
Matthias Löhr	Chairman of Medical & Scientific Advisory Board	2.4yrs	US$16.76k	データなし
Michael Abecassis	Independent Director	6.9yrs	US$38.80k	0.033% $ 5.9k
Wayne Walker	Independent Director	1.5yrs	US$12.50k	0% $ 0
Mark Rabe	Member of Medical & Scientific Advisory Board	no data	データなし	データなし
Jonathan Schechter	Independent Director	1.8yrs	US$31.25k	0.59% $ 104.5k
David Judd	Member of Medical & Scientific Advisory Board	4.9yrs	データなし	データなし

2.4yrs

平均在職期間

64.5yo

平均年齢

経験豊富なボード: PMCBの取締役会は経験豊富ではない ( 2.4年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

PharmaCyte Biotech マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

PharmaCyte Biotech, Inc., Annual General Meeting, Apr 29, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. Announces Resignation of Jack E. Stover as Director

PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer

PharmaCyte Biotech, Inc., Annual General Meeting, Dec 28, 2022

Recent updates

PharmaCyte Biotech, Inc., Annual General Meeting, Apr 29, 2024

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for 7,750,000 shares, for $25.19 million.

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Announces Resignation of Jack E. Stover as Director

PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer

PharmaCyte Biotech, Inc., Annual General Meeting, Dec 28, 2022

PharmaCyte Biotech, Inc. Announces Management Changes

PharmaCyte Biotech says CEO to step down, announces strategic review of business

PharmaCyte Biotech, Inc. Announces Board Appointments

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Iroquois Capital Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech

PharmaCyte Biotech, Inc. Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech, Inc. Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Iroquois Capital Commences Consent Solicitation to Reconstitute Pharmacyte Biotech Board of Directors

Iroquois Capital Issues a Statement in Response to Pharmacyte Biotech

Iroquois Capital Delivers Open Letter to Pharmacyte Biotech Board of Directors

PharmaCyte Biotech, Inc., Annual General Meeting, Aug 25, 2022

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Initiates Studies to Confirm its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech, Inc. Appoints Matthias Löhr to the Board

PharmaCyte Biotech Receives A Notification Letter from Regulation Department of the Nasdaq Stock Market

PharmaCyte Biotech, Inc. Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech, Inc Updates Status of Investigational New Drug Application to FDA

Is This A Good Time To Invest In PharmaCyte?

Pharmacyte Biotech, Inc. Study Proves Capsule Material Is Not Toxic for Encapsulated Cells

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

PharmaCyte Biotech, Inc. Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

PharmaCyte Biotech, Inc. Announces Encapsulation Material Does Not Alter Cellular DNA

Pharmacyte Biotech, Inc. Releases More Positive Results from U.S. Food and Drug Administration-Required Biocompatibility Tests

Pharmacyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

PharmaCyte Biotech: Buy The 'Dump'

PharmaCyte Biotech Common Stock Deleted from Other OTC

PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment

PharmaCyte Biotech, Inc. Announces Update on Study Progress

PharmaCyte Biotech, Inc. Announces Stability Test Results on Cells from Master Cell Bank

PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold

PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for Its Clinical Trial Product

PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for Its Clinical Trial Product

PharmaCyte Biotech, Inc. Successfully Completes 9-Month Stability Study

PharmaCyte Biotech, Inc. Receives U.S. FDA Clinical Hold Letter

PharmaCyte Biotech, Inc. Announces Dr. Gerald W. Crabtree Will No Longer Serve as Chief Operating Officer But Instead Will Serve as Chief Scientific Officer

U.S. FDA Places PharmaCyte Biotech, Inc.’s Investigational New Drug Application on Hold

PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

PharmaCyte Biotech, Inc. Successfully Completes Six-Month Stability Study

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24